Released Nov 3, 2026, after the close
10-Q filed Nov 4, 2026, 35 days after period end · 0001193125-26-446362
Total revenues for the third quarter were $473.6 million, an increase of 7 percent from $441.9 million in the corresponding period last year.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $473.60M | $441.90M | $443.40M | $464.10M |
| Net Income | $31.80M | $12.90M | $33.40M |
Innospec Inc. · CIK 1054905 · Engraved from SEC EDGAR
| $39.20M |
| EPS Diluted | $1.29 | $0.52 | $1.33 | $1.57 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Net income attributable to Innospec was $31.8 million, or $1.29 per diluted share, compared to $12.9 million, or 52 cents per diluted share, last year.¶1
Adjusted EBITDA for the quarter was $51.4 million compared to $44.2 million a year ago, and the quarter closed with net cash of $251.9 million.¶2
The Board declared a semi-annual cash dividend of $0.94 per share, payable November 25, 2026 to shareholders of record as of November 17, 2026.¶3
Performance Chemicals revenues were $180.5 million, up 6 percent from $170.8 million, and operating income was $16.9 million, up 84 percent from $9.2 million.¶4